DDrare: Database of Drug Development for Rare Diseases

Drug DrugBank | All Description Patterns💬 Info on mouse-over

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other

46 / 2,001 drugs

drugs per page:

Showing 1 to 10 of 46 drugs

Filter by

No.	DrugBank	Drug (Description in trials)	KEGG DRUG	KEGG GENES	KEGG PATHWAY On map, Yellow: Drug target genes	Disease ID
1	Adalimumab	[76] Adalimumab; Adalimumab (40 mg); Adalimumab (ada); Adalimumab (d2e7); Adalimumab (humira); Adalimumab (humira®); Adalimumab (up to 9 months exposure); Adalimumab - gp2017; Adalimumab - us licensed humira; Adalimumab 40 mg; Adalimumab 40 mg eow or ew; Adalimumab 40 mg sc every other week; Adalimumab 40 mg subcutaneous (sc) every other week (eow); Adalimumab 40mg q2w; Adalimumab 80 mg; Adalimumab and infliximab; Adalimumab humira; Adalimumab injection; Adalimumab injection [humira]; Adalimumab pfs and pen; Adalimumab prn; Adalimumab with methotrexate; Adalimumab, current formulation; Adalimumab, etanercept, golimumab or infliximab; Adalimumab, new formulation; Adalimumab, plus prednisone; Adalimumab, solution for injection 40 mg/ (0.8 ml) pre-filled syringe; Adalimumab-eu; Adalimumab-pfizer; Amgevita (adalimumab biosimilar ); Anti-tnf therapy (etanercept or adalimumab); Anti-tnf:adalimumab (subcutaneus); Application of adalimumab; Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar product to adalimumab; Ct-p17 sc ai (adalimumab); Db adalimumab 40 mg eow; Db adalimumab 40 mg ew; Device: adalimumab delivered in current autoinjector; Device: adalimumab delivered in current syringe; Device: adalimumab delivered in physiolis autoinjector; Device: adalimumab delivered in physiolis syringe; Diagnostic test: adalimumab serum trough concentration; Diagnostic test: adalimumab trough concentration; Double-blind adalimumab; Etanercept or adalimumab; Fitc-adalimumab; Gp2017 (adalimumab biosimilar); Humira (adalimumab original); Humira (adalimumab); Humira (adalimumab) 40 mg in 0.4 ml s.c. injection; Humira (adalimumab) 40 mg s.c. injection; Humira (adalimumab) 40mg in 0.4 ml s.c. injection; Humira (adalimumab) 40mg in 0.4ml s.c.injection; Humira 40mg solution for injection in pre-filled syringe (adalimumab); Humira ® (adalimumab) 40mg/0.8ml pre-filled syringe; Humira® (adalimumab); Infliximab and adalimumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab, adalimumab, certolizumab pegol; Infliximab, etanercept, adalimumab; Methotrexate,adalimumab; New formulation adalimumab; Ol adalimumab 40 mg; Open-label adalimumab; Open-labeladalimumabrescue; Other: adalimumab; Other: adalimumab treatment; Other: lengthening adalimumab dosing interval; Other: measurement of drug (adalimumab/infliximab); Sb5 (proposed biosimilar to adalimumab); Start adalimumab in monotherapy; Tnf blockers (infliximab, adalimumab, etanercept); Treatment with adalimumab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab);	[1] D02597 💬	[1] TNF 💬	[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway	[16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
2	Amitriptyline	[4] Amitriptyline; Amitriptyline hydrochloride; Amitriptyline, fluoxetine and tramadol alone (control group); Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group);	[2] D00809 D07448 💬	[2] SLC6A2, SLC6A4 💬	[2] Serotonergic synapse, Synaptic vesicle cycle	[4] 78, 97, 226, 299 💬
3	AQX-1125	[3] Aqx-1125; Aqx-1125 100 mg; Aqx-1125 200 mg;	-	-	-	[1] 226 💬
4	Botulinum toxin type A	[6] Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Botulinum toxin type a 200u; Botulinum toxin type a 300u; Botulinum toxin type a infiltrations; Clostridium botulinum toxin type a;	[1] D00783 💬	[1] SNAP25 💬	[2] Insulin secretion, Synaptic vesicle cycle	[13] 2 , 5 , 6 , 7 , 13, 15, 17, 36, 51, 70, 113, 149, 226 💬
5	Buckwheat	[1] Buckwheat;	-	-	-	[1] 226 💬
6	Bupivacaine	[10] Bupivacaine; Bupivacaine hydrochloride; Bupivacaine hydrochloride 0.5% (marcaine, pfizer); Bupivacaine injection 0.5%; Bupivacaine/epinephrine/dexamethasone; Ercp with bupivacaine infusion; Lap tap bupivacaine/epinephrine; Levobupivacaine; Liposomal bupivacaine; Us tap bupivacaine/epinephrine;	[2] D01450 D07552 💬	[5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬	[3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction	[8] 46, 51, 53, 70, 96, 168, 226, 298 💬
7	Cannabidiol	[11] Avcn583601 (3% cannabidiol cream); Cannabidiol; Cannabidiol (cbd); Cannabidiol , synthetic form; Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol botanical drug substance (cbd bds); Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg; Cannabidiol vaginal suppository; Delta-9-tetrahydrocannabinol (thc) and cannabidiol (cbd);	[1] D10915 💬	[2] CNR1, CNR2 💬	[4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis	[19] 2 , 6 , 8 , 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271 💬
8	Capsaicin	[5] Capsaicin; Capsaicin challenge; Capsaicin vapor; Other: challenge agent: capsaicin; Qutenza (8% capsaicin);	[1] D00250 💬	[1] TRPV1 💬	[2] Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction	[5] 2 , 6 , 19, 86, 226 💬
9	Certolizumab pegol	[18] 99mtc-s-hynic certolizumab pegol; Certolizumab pegol; Certolizumab pegol (cdp870); Certolizumab pegol (cdp870, czp); Certolizumab pegol (cdp870, tradename cimzia); Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg); Certolizumab pegol (czp); Certolizumab pegol (czp) 200 mg; Certolizumab pegol (czp) 400 mg; Certolizumab pegol (rinn); Certolizumab pegol + methotrexate (mtx); Certolizumab pegol / cimzia; Certolizumab pegol /cimzia; Certolizumab pegol 200 mg/ml [cimzia]; Certolizumab pegol 400 mg; Cimzia certolizumab pegol 200 mg/ml solution for injection; Infliximab, adalimumab, certolizumab pegol; Pharmacokinetics of certolizumab pegol;	[1] D03441 💬	[1] TNF 💬	[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway	[6] 37, 46, 96, 97, 226, 271 💬
10	Chondroitin sulfate	[4] 2% sodium chondroitin sulfate; Chondroitin sulfate; Hyaluronic acid and chondroitin sulfate; Hyaluronic acid/chondroitin sulfate;	[1] D00080 💬	-	-	[2] 96, 226 💬

First Previous1 2 3 4 5Next Last